Tyrosine News and Research

RSS

Investigational anti-cancer agent ONT-380 shows activity against HER2+ breast cancer

Promising clinical trial results presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show activity of the investigational anti-cancer agent ONT-380 against HER2+ breast cancer, in one case specifically against brain metastases and in another case in overall survival of heavily pretreated HER2+ breast cancer patients.

1 Jun 2015

Clinical utility of Caris Molecular Intelligence in five studies to be presented at ASCO 2015

Caris Life Sciences, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced the presentation of data from five studies that demonstrate the clinical utility of Caris Molecular Intelligence®, the company's panomic comprehensive tumor profiling service, in helping to identify targeted treatment options for patients with rare and/or aggressive tumors.

1 Jun 2015

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

Mirati Therapeutics, Inc. today presented data that demonstrated preliminary evidence of clinical activity from its investigational targeted tyrosine kinase inhibitor candidate, MGCD265, as part of the developmental therapeutics category at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 29-June 2, 2015.

1 Jun 2015

Caris Molecular Intelligence allows comparisons between tumors sharing histological features

Caris Life Sciences, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced the presentation of data from three studies that demonstrate the utility of Caris Molecular Intelligence®, the company's panomic comprehensive tumor profiling service, in facilitating comparisons between tumors that share histological features.

1 Jun 2015

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes in CLL/SLL patients

Today, Pharmacyclics LLC announced the results of the Phase III HELIOS trial (CLL3001), which found that patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who received ibrutinib (IMBRUVICA) in combination with bendamustine and rituximab (BR) experienced an 80% reduction in the risk of progression or death compared to patients receiving placebo in combination with BR.

1 Jun 2015

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Novartis will highlight the strength of its expanded oncology portfolio in 21 medicines and 11 investigational compounds across more than 185 data presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, and the Congress of the European Hematology Association (EHA), June 11-14.

1 Jun 2015

Pharmacyclics initiates ibrutinib-MEDI4736 combination multi-center study for R/R DLBCL or FL

Pharmacyclics, Inc. today announced the initiation of PCYC-1136-CA, a multi-center study that will investigate the use of ibrutinib (IMBRUVICA®) in combination with MEDI4736, an investigational anti-PD-L1 immune checkpoint inhibitor being developed by AstraZeneca.

1 Jun 2015

Updated data from PROCLAIM national patient registry presented at 51st ASCO

Prometheus Laboratories, Inc. announced today the presentation of updated data from the PROCLAIM national patient registry in which first-line Proleukin® (aldesleukin for injection) therapy improved survival in patients with metastatic renal cell carcinoma (mRCC), compared to patients previously treated with targeted therapies.

1 Jun 2015

Preliminary data from ASP2215 Phase 1/2 trial in AML patients presented at ASCO annual meeting

Astellas Pharma Inc. today announced that preliminary data from a Phase 1/2 trial on the safety, tolerability and efficacy of ASP2215, a selective inhibitor of FLT3/AXL, in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) were presented during an oral abstract session at the American Society of Clinical Oncology's annual meeting in Chicago.

30 May 2015

Ibrutinib and chemotherapy reduce risk of death in patients with CLL or SLL

Because of the significant benefit found in combining the targeted drug ibrutinib with standard chemotherapy for relapsed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), an interim analysis has closed the international HELIOS phase III clinical trial.

30 May 2015

Penn researchers to present clinical data at 2015 ASCO Annual Meeting

Researchers from the Abramson Cancer Center of the University of Pennsylvania and Penn's Perelman School of Medicine will present results from several clinical trials and other key studies during the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting from May 29 through June 2.

30 May 2015

Inhibitors BGB324 and BGB10C9 show promise in multiple murine models of pancreatic cancer

BerGenBio AS, an oncology biopharmaceutical company, today announces that an abstract on the latest data on BGB324, the Company's first-in-class, selective small molecule inhibitor of the Axl receptor tyrosine kinase, and BGB10C9, an Axl function-blocking monoclonal antibody in pre-clinical development at BerGenBio, has been published in conjunction with the 2015 American Society of Clinical Oncology Annual Meeting in Chicago, May 29 - June 2, 2015.

30 May 2015

SNPs predict sunitinib outcome in mRCC

Research has confirmed that single nucleotide polymorphisms in genes related to the processing of sunitinib influence the outcome of treatment for metastatic renal cell carcinoma.

29 May 2015

Patient characteristics may guide TKI use in CML

The likelihood of complications associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukaemia may be reduced by considering patient factors and differences in the toxicity profiles of the different drug options, a review suggests.

29 May 2015

High CIP2A may guide TKI choice for chronic phase CML

Treatment with a second-generation tyrosine kinase inhibitor prevents progression to blast crisis in chronic myeloid leukaemia patients with high levels of cancerous inhibitor of PP2A, research suggests.

29 May 2015

Researchers suggest new target for treating BRAF inhibitor-resistant melanoma tumors

A new collaborative study led by researchers at Sanford-Burnham Medical Research Institute, published today in Cell Reports, provides new insight into the molecular changes that lead to resistance to a commonly prescribed group of drugs called BRAF inhibitors.

28 May 2015

Novel drug target identified for treating rheumatoid arthritis

Researchers at the La Jolla Institute for Allergy and Immunology, in collaboration with colleagues the University of California, San Diego, identified a novel drug target for the treatment of rheumatoid arthritis that focuses on the cells that are directly responsible for the cartilage damage in affected joints.

21 May 2015

Merus and Selexis receive a € 2.1 million grant for single cell line manufacturing of a bispecific antibody combination to treat colorectal cancer

Merus and Selexis will combine their unique and proprietary Oligoclonics® and SUREtechnology™ platforms respectively to develop a product combining two bispecific full length IgG antibodies that simultaneously targets and potently inhibits three receptor tyrosine kinases...

20 May 2015

No added benefit with pazopanib over ranibizumab for neovascular AMD

Pazopanib eye drops do not enhance visual outcomes in patients with neovascular age-related macular degeneration beyond those achieved with ranibizumab alone, study findings indicate.

19 May 2015

Promising preliminary results for AKB-9778 in diabetic macular oedema

AKB-9778, a small molecule competitive inhibitor of vascular endothelial-protein tyrosine phosphatase, has a good safety and efficacy profile in patients with diabetic macular oedema, suggests a preliminary dose-escalation study.

19 May 2015

Tyrosine News and Research

Investigational anti-cancer agent ONT-380 shows activity against HER2+ breast cancer

Clinical utility of Caris Molecular Intelligence in five studies to be presented at ASCO 2015

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

Caris Molecular Intelligence allows comparisons between tumors sharing histological features

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes in CLL/SLL patients

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Pharmacyclics initiates ibrutinib-MEDI4736 combination multi-center study for R/R DLBCL or FL

Updated data from PROCLAIM national patient registry presented at 51st ASCO

Preliminary data from ASP2215 Phase 1/2 trial in AML patients presented at ASCO annual meeting

Ibrutinib and chemotherapy reduce risk of death in patients with CLL or SLL

Penn researchers to present clinical data at 2015 ASCO Annual Meeting

Inhibitors BGB324 and BGB10C9 show promise in multiple murine models of pancreatic cancer

SNPs predict sunitinib outcome in mRCC

Patient characteristics may guide TKI use in CML

High CIP2A may guide TKI choice for chronic phase CML

Researchers suggest new target for treating BRAF inhibitor-resistant melanoma tumors

Novel drug target identified for treating rheumatoid arthritis

Merus and Selexis receive a € 2.1 million grant for single cell line manufacturing of a bispecific antibody combination to treat colorectal cancer

No added benefit with pazopanib over ranibizumab for neovascular AMD

Promising preliminary results for AKB-9778 in diabetic macular oedema

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News